GlassScriptPhysician profile
David Dinh Tran
NPI 1184747024
$128,470.06
in general payments reported to CMS, 2019-2025
11 companies · $21K in 2025
The $21K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,547 · 2020: $8,300 · 2021: $7,153 · 2022: $44K · 2023: $27K · 2024: $15K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Honoraria: $16K · Travel and Lodging: $14K · Food and Beverage: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,647.50 |
| Honoraria | $16,385.00 |
| Travel and Lodging | $14,499.18 |
| Food and Beverage | $1,544.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $114,882.27 | 2019-2025 | Optune, Optune Gio, Optune Lua (Novottf-200t) |
| Novocure Gmbh | $9,341.10 | 2022 | |
| Monteris Medical Corporation | $4,055.46 | 2021-2024 | Neuroblate |
| Telix Pharmaceuticals | $132.62 | 2023 | Illuccix |
| Abbott Laboratories | $30.51 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $16.66 | 2022 | |
| Novo Nordisk INC | $11.44 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.